Navigation Links
French Cost-Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time

MOUNTAIN VIEW, Calif., Oct. 28, 2013 /PRNewswire/ -- PneumRx, Inc. (, a leader in the field of interventional pulmonology, today announced that enrollment in the REVOLENS Study, a cost-effectiveness study of the PneumRx RePneu Lung Volume Reduction Coil (RePneu LVRC) in France, has been completed.  The REVOLENS study was submitted last year to the French Ministry of Health by Professors Gaetan Deslee of the University Hospital of Reims and Charles-Hugo Marquette of the University Hospital of Nice and was accepted and funded by the Ministry of Health under the soutien aux techniques innovantes couteuses (STIC) program.  The STIC program provides government funding for innovative medical technologies that have been validated by prior clinical studies, with a view toward establishing reimbursement for new devices.


It was anticipated that the study, which began enrolling subjects in March 2013, would take 12 months to enroll all 100 subjects.  Instead, enrollment was completed in less than 7 months.  This rapid enrollment, which is rare among STIC trials, underscores the need for, and interest in, innovative, minimally invasive treatment options for patients with severe emphysema.

"Having seen the improvements in lung function, exercise capacity and quality of life experienced by the patients we treated in previous trials with the RePneu Coil, we were excited to bring this innovative technology to additional patients via the STIC program.  The patient interest in this trial has been overwhelming," said Professor Gaetan Deslee, Principal Investigator for the study.  "Such a quick enrolment was possible only because of a large commitment of all French teams involved in the treatment of severe COPD patients.  The RePneu LVRC represents an important advancement in the treatment of patients with severe COPD and emphysema, and we look forward to being able to offer the RePneu Lung Volume Reduction as a therapeutic option in the future," said Professor Charles-Hugo Marquette.

The REVOLENS study was one of only two STIC projects selected by the Ministry of Health for funding in 2012, and the first in the field of emphysema treatment since 2006.  The French Government committed to pay 1.3 Million Euros ($1.8 Million) to support this study.

The RePneu LVRC System is a minimally invasive device intended to improve lung function, exercise capacity and quality of life in emphysema patients by bronchoscopically implanting Nitinol coils into the lungs to compress diseased tissue, restore elastic recoil, and re-tension the airway network.  The RePneu LVRC treatment has proven to be effective for a broad range of emphysema patients without requiring any complex diagnostic evaluation.  The RePneu Coil does not block airways, prevent distal access, or destroy lung tissue, but instead provides a simple mechanical solution designed both to treat the key physiologic effects of emphysema and to overcome the key challenges of emphysema treatment.  The RePneu LVRC has proven effective in treating patients with both heterogeneous and homogeneous emphysema, in both upper and lower lobes, and in patients with Residual Volume of 175% predicted and above.  In addition, the RePneu LVRC works independently of collateral ventilation, and is performed in a gentle, well-tolerated procedure with a rapid recovery period.

The RePneu LVRC, which is undergoing a clinical pivotal trial in the United States, has a CE Mark and has been used in over 1500 procedures worldwide, even though the device has been commercially available in Europe for just over 2 years.

"We are thrilled that the French government recognized the benefits of the RePneu Coil and agreed to support this important study," noted Erin McGurk, PneumRx's President and CEO.  "We look forward to bringing the benefits of the RePneu LVRC to growing numbers of emphysema patients in France and throughout the world."

About PneumRx, Inc.
PneumRx, Inc. is a rapidly growing medical device company focused on the development and commercialization of innovative products to treat emphysema using minimally-invasive techniques.  It is a privately held company located in Mountain View, California.

SOURCE PneumRx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. French Man with SynCardia Total Artificial Heart Surpasses Two Years of Support
2. Actavis Receives Approval from French Competition Authority for Pending Warner Chilcott Acquisition
3. French Regulator Lina Ertle, FDAs Jeffrey Baker and Patrick Swann Confirmed Speakers at 2013 PDA/FDA Process Validation Workshop
4. French Lifestyle Secret Finally Revealed: Lycotec Publishes Unexpected Findings on Roquefort Cheese
5. French Government Agrees to Fund Study of the PneumRx RePneu Lung Volume Reduction Coil
6. Pycnogenol® (French Maritime Pine Bark Extract) Shown To Improve Endothelial Function And Reduce Oxidative Stress In New Clinical Trial
7. SWOG Initiates Randomized Phase 2 Clinical Trial of Halozymes PEGPH20 in Combination with modified FOLFIRINOX for Advanced Pancreatic Cancer
8. AstraZeneca Initiates Phase 3 Clinical Trial For Selumetinib In Non-Small Cell Lung Cancer
9. Inovio Pharmaceuticals Therapeutic Vaccine for Hepatitis C Enters Phase I Clinical Trial
10. Thomson Reuters stellt neue Clinical-Trial-Intelligence-Lösung vor
11. Equatorial Guinea Supports Malaria Vaccine Trial
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... ... the No.1 Herpes-only dating community in the world, revealed that over 50% of its members ... billion people under the age of 50 – or 67% of the population - are ... of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder ...
(Date:11/27/2015)... ... 27, 2015 , ... Keeping in mind challenges faced by ... wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for ... parents and bring advice from parenting experts within their reach. As a part ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
(Date:11/26/2015)... ... November 26, 2015 , ... The ... bioavailability and the need to integrate dose form selection in early phase drug ... the membership organization supporting and bringing together the UK’s emerging life sciences companies, ...
(Date:11/26/2015)... ... November 26, 2015 , ... Health-E-minds ... collaborated with Women’s Web – an online resource for Indian women looking ... and emotional well-being relationship, life balance, stress, professional development, and lifestyle. Health-E-minds ...
Breaking Medicine News(10 mins):